Summarized by Masters of Longevity from Longevity Technology.
A biotech–big-pharma licensing deal explained: what readers will learn about a partnered Parkinson’s drug program, delivery tech ownership, and strategic implications.
Key Takeaways
- Genentech paid $100 million upfront to license an engineered enzyme therapy for Parkinson's disease.
- The agreement could add up to $1.17 billion in milestone payments plus tiered royalties on net sales.
